CoChat

Fungämie nach oraler Gabe von Saccharomyces boulardii bei einem multimorbiden Patienten

· 2003 · DMW - Deutsche Medizinische Wochenschrift
Cited by 47

The DOI matches its Crossref record.

Abstract

Anamnese und klinischer Befund: Bei einem 48-jährigen multimorbiden Diabetiker bestand eine generalisierte Mikro- und Makroangiopathie mit einer peripheren arteriellen Verschlusskrankheit im Stadium IV nach Fontaine mit feuchten Nekrosen an beiden Füßen. Er wurde in die Gefäßchirurgie zur femoropoplitealen Bypassversorgung aufgenommen. Untersuchungen: Es waren erhöhte Entzündungsparameter (CRP 66,1 mg/l, Blutsenkungsgeschwindigkeit 90/96), eine An-ämie (Hämoglobingehalt 7,1 mmol/l), eine Leukozytose (14,8 Gpt/l) und eine Thrombozytose (514 Gpt/l) nachweisbar. Die Körpertemperatur war mit 36,8 °C normal. Die Blutzuckerlage war unter Insulintherapie annähernd normoglykämisch (HbA 1c 6,8 %). Therapie und Verlauf: Nach 7-wöchiger intravenöser Therapie mit verschiedenen Breitspektrumantibiotika trat eine Diarrhoe mit positivem Clostridium difficile -Toxinnachweis auf, die nach oraler Gabe von Metronidazol und Saccharomyces boulardii (Perenterol ® ) sistierte. 3 Tage nach der Bypass-Operation wurde aufgrund infizierter Nekrosen mit beginnender Sepsis eine beidseitige Oberschenkelamputation erforderlich, worauf sich der Allgemeinzustand besserte. 8 Tage nach der Bypass-Operation traten ein toxisches Megakolon und eine Sepsis auf. Aus der Blutkultur ließ sich Saccharomyces cerevisiae anzüchten. 5 Tage später starb der Patient trotz Intensivtherapie infolge Multiorganversagens. Folgerung: S. boulardii (Synonym: S. cerevisiae ) ist als apathogene Hefe mit probiotischer Wirkung anerkannt und wird als Lebendorganismus zur Begleittherapie bei Durchfallerkrankungen verwendet. Der vorliegende Fall und die Durchsicht der Fachliteratur zeigen, dass es selten bei immuninkompetenten Patienten zu Fungämien bzw. Sepsisfällen kommen kann. Die Anwendung sollte daher nach kritischer Nutzen-Risiko-Abwägung erfolgen. History and clinical findings: A 48-year-old diabetic with multiple co-morbidities presented with generalized micro- and macroangiopathy including peripheral artery disease stage IV with necroses in several digits of both feet. He was admitted to the department of surgery for the insertion of femoropopliteal bypasses. Investigations: Infectious parameters were elevated (CRP 66.1 mg/l, sedimentation rate 90/96), accompanied by anemia (Hb 7.1 mmol/l), leukocytosis (14.8 Gpt/l) and thrombocytosis (514 Gpt/l). Body temperature was normal (36.8 °C). With insulin treatment the patient became nearly normoglycemic (HbA1c 6.8 %). Treatment and follow up: After receiving different broad-spectrum antibiotics over seven weeks the patient developed Clostridium difficile toxin-positive diarrhea that resolved after administration of oral metronidazole and Saccharomyces boulardii (Perenterol ® ). Three days after bypass insertion, both legs had to be amputated due to infection and beginning sepsis. The condition of the patient improved. However, eight days after bypass-insertion the patient developed a toxic megacolon and sepsis. Blood cultures yielded the growth of Saccharomyces cerevisae . Despite of intensive care treatment the patient died five days later from to multi-organ failure. Conclusion: S. boulardii (synonym: S. cerevisiae ) is considered an non-pathogenic probiotic yeast, and live yeast cells are used for supportive therapy of diarrhea. The present case and a review of the literature demonstrate that fungemia and sepsis are rare complications of the administration of S. boulardii in immunocompromised patients. For this reason the therapeutic usage of probiotics should be carefully considered regarding its risk-benefit potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-2003-44948

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 47

Metadata

Venue
DMW - Deutsche Medizinische Wochenschrift
Published
2003-11
Volume
128
Issue
48
Pages
2531-2533
ISSN
  • 0012-0472 (ISSN-L)
  • 1439-4413
OpenAlex
W2419553116
Cited by
47
References
0
FWCI
1.63
Type
journal article
Language
de
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fungämie nach oraler Gabe von Saccharomyces boulardii bei einem multimorbiden Patienten. https://app.cochat.ai/papers/10.1055/s-2003-44948
The paper
Fungämie nach oraler Gabe von Saccharomyces boulardii bei einem multimorbiden Patienten. (2003). DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-2003-44948

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.